On October 6, 2026, the clinical trial registry listed an update for a study evaluating retatrutide. The trial, titled "A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus," is registered under identifier NCT06982859.
The study is a Phase 1 trial. Its current status is listed as active, not recruiting, meaning the trial is ongoing but no longer enrolling new participants.
The trial focuses on adult participants with type 2 diabetes mellitus and examines retatrutide's effect on insulin secretion and insulin sensitivity in this population. No results have been posted for this trial as of the date of this update.
This brief reports only the status and design details available in the trial registry entry. No efficacy or safety outcomes are included here, as none have been disclosed for this study at this stage.
Readers interested in retatrutide's broader development history and approved uses can consult the compound overview for additional context.